Related Experiment Videos
Development of alkylating agent-resistant human tumor cell lines
1Dana-Farber Cancer Institute, Boston, MA 02115.
Abstract:
Survival curves and dose escalation studies of four representative human tumor cell lines exposed to the various alkylating agents are presented. With HN2, at a level of one log of cell kill there was a fivefold range in drug concentration required to achieve this degree of cell kill among the cell lines, from 4.5 microM for the SL6 lung adenocarcinoma to 22 microM for the SW2 small-cell lung carcinoma. Four logs of SCC-25 squamous carcinoma cells were killed by 100 microM CDDP; however, there was only about one log of SL6 cells killed by 500 microM CDDP. To kill one log of G3361 melanoma cells required 24 microM 4-HC and to kill one log of SCC-25 cells required 24 microM, approximately a 16-fold difference. The curves for cell kill by L-PAM appeared to be biphasic, with a break at about 100 microM. There was about a threefold range in drug concentration required to achieve one log of cell kill with L-PAM, from 60 microM in the SCC-25 cell line to 18 microM in the SW2 line. To kill one log of SCC-25 cells required 295 microM BCNU and to kill one log of SW2 cell required 120 microM, about a 2.5-fold difference. The range of maximally tolerated HN2 concentrations were from 1200 microM for the SL6 cell line, 48 times the initial concentration, to 300 microM for the SCC-25 line, 16 times the initial concentration. The G3361 line tolerated the highest level of CDDP, 1900 microM, 48 times the initial concentration. The SCC-25 line, on the other hand, tolerated only 600 microM, 30 times the initial concentration. The SL6 cell line maximally tolerated 36 times the initial concentration of 4-HC (1450 microM), whereas the SCC-25 cell line tolerated only 18 times the initial concentration (720 microM). The G3361 melanoma tolerated 1555 microM, 30 times the initial concentration of L-PAM, and the SCC-25 cell line tolerated 700 microM, 14 times the initial concentration. The SL6 cell line tolerated the highest concentration of BCNU, 4200 microM, 24 times the initial concentration. The SCC-25 cell line tolerated 1450 microM, 8 times the initial concentration. In all cases, the SCC-25 cell line was least able to tolerate exposure to increasing concentrations of alkylating agents. The SL6 and G3361 cell lines showed the greatest tolerance for increasing concentrations of alkylating agents.(ABSTRACT TRUNCATED AT 400 WORDS)
Insights
This study reveals significant variations in how human tumor cell lines respond to alkylating agents, with SCC-25 cells being the most sensitive and SL6/G3361 cells showing higher tolerance. These findings are crucial for personalized cancer treatment strategies.
Area of Science:
- Pharmacology and Toxicology
- Cancer Cell Biology
- Chemotherapy Research
Background:
- Alkylating agents are a cornerstone of cancer chemotherapy.
- Tumor cell lines exhibit differential sensitivity to chemotherapeutic drugs.
- Understanding inter-cell line variability is key to optimizing treatment.
Purpose of the Study:
- To evaluate the dose-response relationships of four human tumor cell lines to various alkylating agents.
- To compare the sensitivity and tolerance of different cell lines (SL6, SW2, SCC-25, G3361) to HN2, CDDP, 4-HC, L-PAM, and BCNU.
- To identify patterns of drug resistance and sensitivity among these representative cancer models.
Main Methods:
- Survival curves were generated for four human tumor cell lines.
- Dose escalation studies were performed using HN2, CDDP, 4-HC, L-PAM, and BCNU.
- Quantification of drug concentration required for specific log cell kill and maximal tolerated concentrations were determined.
Main Results:
- Significant variability in drug concentration for one log cell kill was observed across cell lines for all agents tested (e.g., HN2: 4.5 microM for SL6 vs. 22 microM for SW2).
- SCC-25 cells demonstrated the lowest tolerance to increasing concentrations of alkylating agents, while SL6 and G3361 cells exhibited the greatest tolerance.
- Specific examples include: 100 microM CDDP killed 4 logs of SCC-25 cells, but only 1 log of SL6 cells; SCC-25 tolerated 600 microM CDDP, while G3361 tolerated 1900 microM.
Conclusions:
- Human tumor cell lines display marked heterogeneity in their response to alkylating agents.
- The SCC-25 cell line is consistently more sensitive and less tolerant to these chemotherapeutics compared to SL6 and G3361.
- These differential responses underscore the importance of considering individual tumor cell characteristics in the development of targeted chemotherapy regimens.